Core Viewpoint - The stock price of Fuhong Hanlin (2696.HK) surged over 11% to reach a new high of 75 HKD, with a market capitalization exceeding 40 billion HKD, reflecting a reassessment of its long-term growth value in the innovative drug sector [1] Group 1: Stock Performance - The company's stock has been rising for multiple trading days since last week, driven by a strong performance in the innovative drug sector [1] - The market capitalization surpassing 40 billion HKD indicates recognition of the company's global strategy and continuous innovation capabilities [1] Group 2: Recent Developments - The company announced several innovative drug research results selected for the World Lung Cancer Conference (WCLC), including PD-L1 ADC and the combination therapy with Surulitinib [1] - The self-developed biosimilar HLX14 received a positive opinion from the European Medicines Agency (CHMP), marking a significant step towards European market entry [1] - Surulitinib's lung cancer indication has been approved in the UK and India, with commercial shipments initiated in India, the world's most populous country [1] Group 3: Product Pipeline - The company has multiple products approved for sale globally, with ongoing clinical and registration efforts in overseas markets [1]
复宏汉霖(2696.HK)市值突破400亿港元，创新药行情催化估值上行